Streetbeat News

Stock Prices

CYTH

Cyclo Therapeutics has completed the enrollment of the last patient in its Phase 3 TransportNPC trial for Niemann-Pick Disease Type C1. The trial is the most comprehensive study for NPC1 treatment, and topline data from the 48-week interim analysis of 104 patients is expected in H1 2025.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 1:04 pm

FTHM

VHC

VIVK

WOOF

The article highlights notable insider transactions for penny stocks, including Fathom Holdings, Petco Health and Wellness, VirnetX Holding, and Vivakor. These transactions indicate insider confidence in these companies.

Portfolio Pulse from Avi Kapoor

May 30, 2024 | 1:03 pm

DXCM

DexCom (NASDAQ:DXCM) has been analyzed by six analysts, revealing a range of sentiments from bullish to indifferent. The average 12-month price target has increased to $154.0, with a high estimate of $165.00 and a low estimate of $130.00. Recent ratings include a mix of 'Strong Buy', 'Buy', 'Outperform', and 'Neutral'. DexCom's financial health is strong, with notable revenue growth, high net margins, and effective asset utilization, though it carries a substantial amount of debt.

Portfolio Pulse from Benzinga Insights

May 30, 2024 | 1:01 pm

BCDA

BioCardia shares have resumed trading after a temporary halt. This development is significant for investors as it may impact the stock's short-term price movement.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 1:01 pm

SYK

Analysts have provided mixed ratings for Stryker (NYSE:SYK) over the past three months, with a recent increase in price targets. The average 12-month price target is now $381.5, up 6.27% from the previous $359.00. Despite a recent revenue decline, Stryker maintains strong financial health with high net margins, ROE, and ROA, and a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

May 30, 2024 | 1:00 pm

ELV

Elevance Health (NYSE:ELV) has been analyzed by 12 analysts over the past three months, showing a range of perspectives from bullish to bearish. The average 12-month price target has increased by 3.07% to $595.0. Analysts have recently raised their ratings and price targets, reflecting positive sentiment towards the stock. Key financial metrics such as revenue growth, net margin, ROE, and ROA are strong, although the company faces challenges in debt management.

Portfolio Pulse from Benzinga Insights

May 30, 2024 | 1:00 pm

LYFT

Analysts have provided mixed ratings for Lyft (NASDAQ:LYFT) over the past three months, with a recent increase in average 12-month price targets. The average target is now $19.47, up 17.57% from the previous $16.56. Analysts from firms like Goldman Sachs, Citigroup, and RBC Capital have raised their price targets, reflecting a more optimistic outlook.

Portfolio Pulse from Benzinga Insights

May 30, 2024 | 1:00 pm

EQR

Over the past three months, 11 analysts have evaluated Equity Residential (NYSE:EQR), showing a range of sentiments from bullish to bearish. The average 12-month price target has increased by 3.04% to $68.91. Recent analyst actions include several rating raises and one downgrade, reflecting a generally positive outlook.

Portfolio Pulse from Benzinga Insights

May 30, 2024 | 1:00 pm

BCDAW

Trading halt status was updated at 9:00:00 AM ET, with quotation resumption times provided. The news specifically mentions BCDAW.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 1:00 pm

LVO

LiveOne has announced its FY25 consolidated revenue guidance, expecting between $140 million and $155 million, with an estimate of $148.884 million.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 12:57 pm